Burning rock to release mrd clinical data on nsclc and crc at the upcoming american association for cancer research annual meeting

Guangzhou, china, march 15, 2022 (globe newswire) -- burning rock biotech limited (nasdaq: bnr, the “company” or “burning rock”) today announced that it will present mrd (molecular residual disease) clinical data on non-small cell lung cancer (nsclc) and colorectal cancer (crc) at the following two sessions of american association for cancer research (aacr) annual meeting on april 8, 2022:
BNR Ratings Summary
BNR Quant Ranking